Epigenomics validates test for colorectal cancer biomarker Septin 9
This article was originally published in Clinica
Executive Summary
Molecular diagnostics company Epigenomics has successfully validated an improved assay and an enhanced testing algorithm for its colorectal cancer biomarker, Septin 9, in two independent clinical studies. The disease has a five-year-survival rate of more than 90% if it is diagnosed at an early stage: consequently, early detection is crucial.